Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients by Ljung, Rolf et al.
Eur J Haematol. 2019;102:111–122.	 wileyonlinelibrary.com/journal/ejh	 | 	111
 
Received:	30	July	2018  |  Revised:	25	October	2018  |  Accepted:	29	October	2018
DOI:	10.1111/ejh.13193
R E V I E W  A R T I C L E
Inhibitors in haemophilia A and B: Management of bleeds, 
inhibitor eradication and strategies for difficult‐to‐treat 
patients
Rolf Ljung1,2 | Guenter Auerswald3 | Gary Benson4 | Gerry Dolan5 | Anne Duffy6 |  



























replacement	 factor	 VIII	 (FVIII)	 or	 factor	 IX	 (FIX).	 Patients	 who	 develop	 inhibitors	
against	FVIII/FIX	face	an	increased	risk	of	bleeding,	and	the	likelihood	of	early	devel‐
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the	 caregivers	 of	 children	with	 inhibitors,	 disappointment,	 isolation	
and	general	strain	were	significant	among	the	reported	burdens.9
While	 the	 recently	 approved	 non‐factor	 therapy,	 emicizumab	





high‐titre	 inhibitors	 is	 antibody	 eradication	 via	 immune	 tolerance	







ITI	may	 also	 be	 attempted	 in	 patients	with	 haemophilia	B	 and	
high‐titre	FIX	inhibitors,	but	it	is	utilised	less	frequently	than	in	those	
with	haemophilia	A	due	to	a	general	lack	of	experience	of	its	use	in	
haemophilia	B	 and	 lower	overall	 success	 rates,	 as	well	 as	 concern	
about	 anaphylactic	 reactions	 and	 development	 of	 nephrotic	 syn‐
drome.2,3,13	The	lack	of	data	for	 ITI	 in	patients	with	haemophilia	B	
and	 inhibitors	means	 that	 the	optimal	approach	 for	achieving	suc‐
cessful	outcomes	in	these	patients	has	not	been	clarified.2,13
This	review	summarises	currently	available	treatment	options	for	
patients	with	 inhibitors,	 starting	with	 the	 treatment	of	bleeds	and	











derived	 activated	 prothrombin	 complex	 concentrate	 (pd‐aPCC;	
FEIBA®,	 Shire,	 Lexington,	 KY,	 USA).3,18‐20	 The	 FEIBA	 NovoSeven® 


















with	haemophilia	and	 inhibitors,	 since	 the	presence	of	age‐related	
on	ITI	regimens	and	those	ITI	strategies	that	may	be	used	in	difficult‐to‐treat	patients.	
Some	alternative,	non‐ITI	approaches	for	inhibitor	management,	are	also	proposed.
K E Y W O R D S
coagulation	disorders,	paediatric	haematology,	quality	of	life
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comorbidities	adds	further	complications	to	an	already	complex	clin‐
ical	scenario.24












subcutaneously.26,27	 Phase	 III	 trial	 data	 showed	 that,	 in	 patients	
with	haemophilia	A	and	inhibitors,	emicizumab	prophylaxis	was	as‐
sociated	with	a	significant	reduction	in	the	annualised	bleeding	rate	
compared	with	 no	 prophylaxis	 (P	<	0.001).26	 A	 good	 safety	 profile	
was	reported	for	emicizumab	administered	alone	or	 in	conjunction	
with	rFVIIa	alone.	However,	in	this	study,	thrombotic	microangiopa‐
thy	and	 thrombosis	 (in	 two	participants	each)	developed	 following	
administration	 of	 multiple	 infusions	 of	 pd‐aPCC	 for	 breakthrough	
bleeds	while	 receiving	 emicizumab	prophylaxis;	 this	 resolved	 after	
pd‐aPCC	treatment	was	stopped.26	Another	trial	participant	receiv‐






rFVIIa	as	a	 first‐line	 treatment	 for	breakthrough	bleeds	 in	patients	
on	 emicizumab	 prophylaxis,	 with	 close	 observation	 for	 thrombo‐
sis.	While	 pd‐aPCC	 can	 be	 used	 if	 there	 is	 no	 response	 to	 rFVIIa,	
or	 if	 other	options	 (such	as	FVIII)	 are	not	 available	or	 appropriate,	
treatment	should	be	administered	 in	hospital	with	careful	monitor‐
ing.25	 In	 addition	 to	 the	 above	 fatality,	 a	 further	 four	 deaths	 have	
subsequently	been	reported	in	adults	treated	with	emicizumab,	one	
of	whom	was	being	treated	in	the	US	expanded	access	programme	
and	 three	under	 compassionate	use	 requests.29	As	with	 the	death	
during	the	phase	III	trial,	 in	all	four	of	these	instances,	the	treating	
physician	considered	that	the	cause	was	unrelated	to	emicizumab.29
While	 emicizumab	 prophylaxis	 provides	 an	 alternative	 treat‐
ment	 option	 for	 patients	 with	 haemophilia	 A	 and	 inhibitors,	 in	
general,	 the	authors	do	not	recommend	that	emicizumab	be	con‐
sidered	 a	 first‐line	 therapy	 but	 rather	 as	 a	 rescue	 treatment	 for	
patients	 with	 persistent	 inhibitors.	 Most	 patients	 will	 eventually	





use	 of	 emicizumab	 and	 a	 bypassing	 agent	may	 also	 increase	 the	
risk	of	adverse	events	(AEs).	The	authors	recommend	considering	
emicizumab	prophylaxis	in	patients	who	wish	to	delay	ITI	to	allow	
the	 inhibitor	 titre	 to	 fall	 to	 <10	 Bethesda	 units	 (BU)/mL,	 in	 very	
















sensus	 guidelines,	 and	 the	UKHCDO	guidelines	 all	 recommending	
rFVIIa	as	the	prophylactic	agent	of	choice	prior	to	ITI.2,30,31	During	
TA B L E  1  Frequently	used	definitions	of	successful,	partially	successful,	and	unsuccessful	ITI	in	patients	with	haemophilia	A	with	
inhibitors,	adapted	from	Benson	et	al17































4  | IMMUNE TOLER ANCE INDUC TION
4.1 | Defining the outcome of ITI
It	is	important	to	establish	firm	definitions	not	only	of	ITI	success,	but	
also	when	treatment	has	not	succeeded.	Widely	adopted	definitions	
of	 successful,	 partially	 successful,	 and	 unsuccessful	 ITI	 for	 patients	








ITI	 for	patients	with	haemophilia	A	and	 inhibitors	 (Table	1)	does	not	
allow	for	improvement	in	the	clinical	phenotype.17,32	A	survey	designed	
to	 develop	 a	 consensus	 definition	 of	 unsuccessful	 ITI	 for	 Australian	
clinical	 practice	 identified	 clinical	 outcomes	 as	 important	 factors	 for	
assessing	 ITI	 response,	 leading	 to	 the	 conclusion	 that	 a	 reduction	 in	
bleeding	symptoms	alone	may	be	sufficient	to	justify	continuing	ITI.32










4.2 | Conventional methods for ITI














binant	 factor	 concentrates,	 there	 is	 now	much	 discussion	 regarding	







4.3 | Predictors of outcome of conventional ITI
Reports	 on	 ITI	 outcomes	 collected	 in	 several	 international	 regis‐
tries,	albeit	not	always	in	agreement,	have	enabled	the	identifica‐
tion	 of	 numerous	 treatment‐	 and	 patient‐related	 factors	 that	 are	
predictive	of	ITI	outcome.17,38	Treatment‐related	factors	that	may	
influence	ITI	outcome	include	inhibitor	titre	at	ITI	onset,	the	time	
elapsed	 between	 inhibitor	 diagnosis	 and	 initiating	 ITI,	 historical	
peak	 inhibitor	 titre,	 and	 peak	 inhibitor	 titre	 during	 ITI	 (Table	 3).	
An	 inhibitor	 titre	of	<10	BU/mL	at	 ITI	onset	 is	 recognised	as	one	
































BID,	 twice	daily;	FVIII,	 factor	VIII;	 ITI,	 immune	tolerance	 induction;	 IV,	
intravenous;	 IVIG,	 intravenous	 immunoglobulin;	 pd‐aPCC,	 plasma‐de‐
rived	activated	prothrombin	complex	concentrate;	PO,	by	mouth.
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Monitor patients with haemophilia at risk of developing inhibitors
  PREVENTION
• Identify patients at risk of 
 developing inhibitors (risk
 factors include genetic
 background, family history)
• Promote preventive measures
 that could reduce the risk 
 of inhibitor development
• Monitor inhibitor development
 carefully in all patients 
 DETECTION
• Early and frequent screening
 of inhibitor development via 
 blood tests
• Follow up with confirmation
 and quantitation of the 
 inhibitor concentration
 (Bethesda or Nijmegen-
 Bethesda assay)
 DECISION
• Patient can be referred 
 to a haemophilia care centre 
 with experience in inhibitor 
 management
• Validate treatment plan 
 by experts
• Discuss with the patient 
 inclusion in a registry
Current management of patients with haemophilia and inhibitors
INHIBITOR ERADICATION (PREFERRED STRATEGY)
• Inhibitor eradication via ITI with replacement factor
• ITI in children:
 • Standard of care
 • Good success reported
• ITI in adults:
 • Not widely accepted, limited validation,
  scarce experience
 • Consider a first course of ITI
   TREATMENT OF BLEEDS
• Manage bleeding episodes using bypassing agents:
 rFVIIa (NovoSeven®) or aPCC (FEIBA)
   PROPHYLAXIS
• Selected patients may benefit from prophylaxis with 
 emicizumab or bypassing agents (rFVIIa* or aPCC)
 PATIENT RESPONSE TO ITI
• Quantitate inhibitor titre
• Evaluate FVIII pharmacokinetics
• Monitor patient’s clinical phenotype
Assessment of ITI response
Current therapeutic options in patients with persistent inhibitor after unsuccessful ITI
 SUCCESS
• Full success according to the 
 standard definition2
• Continue prophylaxis with same
 concentrate as used during ITI
NO SUCCESS OR PARTIAL SUCCESS
Need to consider:
• The residual inhibitor titre
• Clinical response to FVIII
• The patient’s bleeding phenotype, age,
 clinical response to bypassing agents
 and joint status
 PROPHYLAXIS
• Prophylaxis with factor 
 concentrates in some patients
 with low-titre inhibitors, or partial
 response to ITI
• Selected patients may consider 
  prophylaxis with emicizumab or
  bypassing agents (rFVIIa*
  or aPCC)
 TREATMENT OF ACUTE 
 BLEEDS
• On-demand treatment with 
 bypassing agents (rFVIIa 
 or aPCC)
 SECOND-LINE ITI
• New ITI attempt with a different
 regimen
 • Try a different factor concentrate
 • Use a higher dose or twice-daily
  administration of factor
 • Consider the association
  of an immunosuppressive
  protocol (eg, adding rituximab
  to the current ITI regimen)











ies	have	 investigated	the	effect	of	FVIII	mutation	 type	on	 ITI	out‐
come,39,51,52	and	large	cohort	studies,	in	which	other	risk	factors	can	
be	taken	into	account,	are	needed	to	assess	the	impact	of	genotype.
4.4 | ITI strategies for difficult‐to‐treat patients
An	algorithm	to	assist	the	management	of	patients	with	inhibitors	is	
shown	in	Figure	1.





















tion	of	B	 lymphocytes,	 is	hypothesised	to	facilitate	the	 induction	of	
immune	tolerance	 in	resistant	 inhibitor	cases.53	While	rituximab	has	
primarily	 shown	 promise	 in	 the	 treatment	 of	 inhibitors	 associated	
with	acquired	haemophilia,	a	number	of	case	studies	in	patients	with	
congenital	 haemophilia	 and	 inhibitors	unresponsive	 to	 ITI	 have	 also	










completely	normalise	 in	 two	patients.54	 It	 is	 important	 to	note	 that	
information	on	the	long‐term	safety	of	rituximab	is	still	lacking	and	this	
has	raised	concerns	regarding	its	use,	particularly	in	children.53
4.4.2 | Adults and older patients with inhibitors
There	 is	 resistance,	by	both	patients	and	physicians,	 to	 initiate	 ITI	
in	adults	with	haemophilia	and	inhibitors,	mainly	related	to	the	per‐
ceived	 poor	 prognosis,	 demanding	 treatment	 regimens	 and	 high	
costs.58	However,	as	discussed	above,	age	at	ITI	initiation	should	be	
considered	 in	a	 larger	 framework	of	putative	prognostic	 factors,58 
because	older	 age	when	 starting	 ITI	may	not	 adversely	 affect	 the	
outcome	in	adult	patients	with	recent‐onset	inhibitors.49	In	a	retro‐
spective	observational	study	of	nine	patients	with	severe	or	mod‐
erately	 severe	 (≤2%	 FVIII	 activity)	 haemophilia	 and	 long‐standing	
inhibitors	 (4‐31	yrs)	 who	 underwent	 late	 ITI	 utilising	 recombinant	
FVIII	 products	 (regimens	 ranged	 from	50	IU/kg/3	 times	 per	week	
to	100	IU/kg/daily),	 seven	achieved	either	partial	or	 full	 success.59 
Similarly,	in	another	study,	11	of	12	adult	patients	(<2%	FVIII	activ‐
ity),	with	>24	months	between	inhibitor	diagnosis	and	ITI,	achieved	
either	 complete	 or	 partial	 success	 using	 a	 single	 vWF‐containing	
plasma‐derived	FVIII	(pdFVIII)	product.49
Although	ITI	is	associated	with	high	costs	in	adults,	a	study	inves‐




In	 the	authors’	view,	 the	current	data	suggest	 that	a	course	of	
conventional	 ITI	may	 be	 justified	 in	 selected	 adults;	 however,	 the	








and	 the	 impact	 of	 second‐line	 therapy.	 With	 little	 in	 the	 way	 of	







































fectiveness	 of	 conventional	 ITI.63‐65	Nevertheless,	 in	 the	 INSIGHT	
study	(International	Study	on	Etiology	of	Inhibitors	in	Patients	with	
a	Moderate	or	Mild	Form	of	Hemophilia	A,	 Influences	of	 Immuno‐

























was	 achieved	 using	 combined	 immune‐modulating	 therapy	 (rituxi‐
mab,	mycophenolate	mofetil,	dexamethasone,	and	 intravenous	 im‐
munoglobulins)	and	high‐dose	FIX.69	Following	re‐emergence	of	FIX	
inhibitors	 7	years	 later,	 this	 patient	 was	 again	 effectively	 treated	
using	the	same	regimen.73
4.5 | Managing the psychosocial impact of 
unsuccessful ITI
In	the	light	of	the	psychosocial	burden	imposed	on	patients	and	car‐
egivers	 by	 inhibitors	 and	 their	management,	 psychologists	 should	
be	 included	 in	any	comprehensive	care	 team	alongside	physicians,	
nurses,	social	workers,	and	physical	and	occupational	therapists.8,11 
This	ensures	that	treatment	plans	encompass	both	physical	and	psy‐









mended	 to	maintain	 an	 attitude	 of	 hope	 for	 the	 future,	 deal	with	






5  | ALTERNATIVE NON‐ITI  TRE ATMENT 














be	 carried	 out	 in	 the	 inpatient	 setting	 that	 has	 experience	 of	 this	
treatment,	along	with	careful	monitoring.
Another	 form	of	 combination	 therapy	 involves	 the	 administra‐
tion	of	FVIII	with	either	rFVIIa	or	pd‐aPCC.	An	in	vitro	study	using	






main	 deleted	 porcine	 FVIII	 (OBI‐1),	 demonstrated	 efficacy	 and	










other	 non‐factor	 therapies	 include	 improved	 compliance	 due	 to	
more	 convenient	 subcutaneous	 (rather	 than	 intravenous)	 admin‐
istration.	 Promising	 early	 results	 have	 been	 demonstrated	 with	
concizumab,	a	humanised	monoclonal	antibody	targeting	anti‐tis‐
sue	factor	pathway	inhibitor	(TFPI)12:	there	were	no	serious	AEs	in	
concizumab‐treated	 patients	with	 haemophilia	A	 or	B;	 improved	
thrombin	 generation	was	 observed	 in	 patients	with	 haemophilia	
A	 and	 B	 and	 in	 plasma	 samples	 from	 patients	 with	 haemophilia	
A	and	 inhibitors.80,81	Two	other	monoclonal	antibodies	 targeting	
TFPI	 (BAY	1093884	and	PF‐06741086)	 are	 in	development.	The	
PK	and	pharmacodynamics	have	been	investigated	in	animal	and/
or	 in	 vitro	 models;82‐84	 phase	 I	 (BAY	 1093884;	 NCT03481946	
and	 NCT02571569)	 and	 phase	 II	 (PF‐06741086;	 NCT02974855	
and	 NCT03363321)	 clinical	 studies	 are	 ongoing.	 Another	 novel	
agent	currently	under	 investigation	is	fitusiran	(ALN‐AT3),	a	syn‐




observed	 in	 fitusiran‐treated	 patients,	 although	 a	 participant	 in	
the	phase	II	open‐label	extension	trial	suffered	a	fatal	thrombotic	
event.86,87	 Two	 phase	 III	 trials	 investigating	 efficacy	 and	 safety	
of	 fitusiran	 in	patients	with	haemophilia	A	or	B	with/without	 in‐










These	molecules	 could	provide	more	options	 for	patients	with	 in‐
hibitors	 for	on‐demand	or	surgical	 treatment	 (OBI‐1	and	rVIIa‐FP),	






and	 consensus	 recommendations	 are	 valuable,	 clinical	 experience	
continues	to	play	a	major	role.	This	is	especially	the	case	when	man‐
aging	 difficult‐to‐treat	 patients,	 such	 as	 those	who	 are	 unrespon‐
sive	to	first‐line	ITI,	older	patients,	and	those	with	mild	haemophilia	
A,	haemophilia	B,	or	predictors	of	poor	 response.	Acute	bleeds	 in	
patients	 unresponsive	 to	 ITI	 can	be	 treated	with	 on‐demand	hae‐
mostatic	 therapy,	 such	as	bypassing	agents.	Furthermore,	prophy‐
laxis	with	bypassing	agents	or,	 in	haemophilia	A,	with	emicizumab	
may	be	effective	 for	patients	not	currently	 receiving	 ITI,	 including	
those	 in	whom	 ITI	has	previously	been	unsuccessful.	The	 inability	
to	 achieve	 successful	 ITI	 in	 20%‐40%	 of	 patients,	 the	 high	 costs	
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